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A series of expression vectors has been constructed as based on the pML derivative of pBR322. The eukaryotic transcription units employ various 
promoters followed by polycloning sites for 3-9 commonly used restriction enzymes and are completed by the SV40 polyadenylation sequence. 
In 4 of the vectors, designed for co-transfection or transient expression studies, only a single transcription unit containing either a constitutive 
or an inducible promoter was incorporated. The human ubiquitin (UbC) promoter was used as a strong constitutive promoter, while the mouse 
metallothionein promoter and the promoter of the long terminal repeats of the mouse mammary tumor virus were used as inducible promoters. 
Another vector contained an additional transcription unit encoding a eukaryotic selection marker, the neomycin resistance ncoding gene. The 
vectors were used in CHO cells and in neuroendocrine CA77 cells to synthesize peptide precursors, protease inhibitors and a protease. It is shown 
that these vectors are very efficient for the constitutive and inducible expression of nucleotide sequences in both transient and stable transfections 
of eukaryotic ells. 
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1. INTRODUCTION 
Biosynthesis of biologically active eukaryotic pro- 
teins frequently requires posttranslational modifica- 
tions [l]. Many of these are not performed by, for 
example, bacterial cells. Therefore, biosynthesis of 
functional eukaryotic proteins encoded by cloned 
nucleotide sequences often has to be performed in 
eukaryotic cells. This is the case, for example, in the 
biosynthesis of many eukaryotic secretory proteins for 
structure-function studies [2,3]. The synthesis of ex- 
ogenous protein in eukaryotic cells requires transfec- 
tion of the exogenous DNA integrated in an eukaryotic 
expression vector [4]. 
As the vectors have to be multiplied in bacteria prior 
to transfection of the eukaryotic cells, any eukaryotic 
expression vector must contain sequences which 
facilitate the prokaryotic propagation along with one 
or more eukaryotic transcription units. The prokaryo- 
tic sequences usually include a bacterial resistance gene 
and an origin of DNA replication which functions in 
bacteria. The eukaryotic transcription unit should con- 
sist of a powerful eukaryotic promoter (inducible or 
constitutive), a polyadenylation signal, and finally a 
polylinker for insertion of nucleotide sequences en- 
coding the protein in question [4]. The early eukaryotic 
expression vectors (see e.g. [5-71) all contained con- 
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stitutive virus promoters. The polylinker of otherwise 
useful vectors like pMSG (Pharmacia), pMT2 [8] or 
pUANL [9] are not very useful in general. We describe 
the construction and function of a series of small ver- 
satile eukaryotic expression vectors containing strong 
constitutive or inducible promoters and an extensive 
polylinker . 
2. MATERIALS AND METHODS 
2.1. Vector construction 
The basic vector contains a 53 bp fragment from the pIC19R [lo] 
polylinker (EcoRI to BamHI) ligated into pML [l l] between EcoRI 
and .SaiI, 2344 bp. Prior to ligation the SaiI site had been converted 
to a BamHI site by BamHI linkers. The simian virus 40 (SV40) 
polyadenylation signal, a 237 bp BamHI to BciI fragment correspon- 
ding to position 2451-2688 of the SV40 genome [12], was inserted in- 
to the BamHI site of this vector in two different orientations, thereby 
regenerating one BamHI site. This fragment contains two 
polyadenylation signals on one strand and one on the other [12]. In 
the vector where the regenerated BamHI site was located between the 
polylinker and the polyadenylation signal, the polylinker was extend- 
ed with EcoRI and SmaI by insertion of a 24 bp BamHI/BgAI frag- 
ment from the polylinker of pSP6/T3 (Pharmacia) into the BamHI 
site. Prior to insertion, the original EcoRI site was removed. This vec- 
tor (pSV-LIC) was the basic vector used for construction of the 
pTEJ-series, except for pTEJ-3A. 
pTEJ-3A which contains the constitutive human ubiquitin (UbC) 
promoter [13,14], was based on the vector where the 237 bp 
BamHI/BciI SV40 fragment was inserted in the orientation which 
regenerated the BamHI site at the 3 ’ end. This vector contains a uni- 
que HpaI site between the polylinker and the polyadenylation signal 
1121. The human ubiquitin promoter, as an approximately 1500 bp 
Hind111 fragment, was excised from ~753 [13] (obtained from Dr E. 
00145793/90/$3.50 0 1990 Federation of European Biochemical Societies 289 
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Boel, Nova-Nordisk, Copenhagen), and inserted into the Hind111 site 
of this vector (Fig. 1). The promoter in the XHUb13 clone [14], was 
originally excised as a XhoI fragment, covering the region from posi- 
tion approximately -1450 to +43 in the ubiquitin gene. Putative 
TATA box and cap site are located at position -74 and -44, respec- 
tiveiy [14]. 
pTEJ-4 was constructed by insertion of the Hind111 fragment of 
the human ubiquitin promoter [13] into the Hind111 site of pSV-LIC, 
followed by a selective repair of the staggered ends of the Hind111 site 
located at the 5’ end of the ubiquitin promoter, in order to preserve 
the Hind111 site as a unique site in the polylinker (Fig. 1). 
pTEJ-5 contains the inducible promoter of the mouse metallothio- 
nein 1 gene [15] (Fig. 1). The promoter was excised as a 250 bp Bg/I- 
BgfiI fragment corresponding to position -185 to +65 of the mouse 
metallothionein 1 gene [IS] (obtained from Dr R. Palmiter, Universi- 
ty of Washington, Seattle) and converted to a blunt-ended fragment 
by Klenow polymerase. The fragment was then ligated into the 
EcoRV site of pSV-LIC. 
pTEJ-7 was constructed by inserting the long terminal repeat of 
mouse mammary tumor virus [16] into pSV-LIC. The promoter was 
excised from pMSG (Pharmacia) as a 1471 bp Hind111 to XhoI frag- 
ment, corresponding to position 6182-18, which was converted to 
blunt end and ligated into the EcoRV site of pSV-LIC (Fig. 1). 
pTEJ-8 is a derivative of pTEJ-4 containing the neomycin 
phosphotransferase encoding gene, neo [17] under control of SV40 
early promoter (Fig. 2). The SV40 early and late promoters, 
Hpal 
Mndlll, Sa/l EC&I, BamHl 
WY----- 
Xba 
enhancer, and origin of DNA replication were excised as a 326 bp 
Hind111 to PvuII fragment corresponding to position 5085 to 189 of 
the SV40 genome [12]. This fragment was converted to blunt ends 
and ligated into the blunt end converted Bg/II site of pTEJ-4. This 
new plasmid has the SV40 early promoter operating in the opposite 
direction to the ubiquitin promoter (see Fig. 2). The neo gene was in- 
serted into the EcoRV site, under the control of the SV40 early pro- 
moter, as a blunt end converted 1238 bp BarnHI to DruI fragment. 
This fragment excised from ~753, also contains the SV40 
polyadenylation signal at the 3’ end of the neo gene [13] (Fig. 2). 
2.2. Transfection 
CHO cells for transfection were seeded in 80 cm’ flasks (Costar) at 
a density of l@ per cm’. After 24 h the cells were transfected with 
20 fig of DNA using the calcium phosphate precipitate procedure of 
Graham and Van der Eb [20]. Cotransfection experiments were per- 
formed with 19,ug of the specific transfection plasmid and 1 gg of 
pSV2-neo [5]. CHO cells were grown at 5% CO2 in RPM1 1640 sup- 
plemented with 10% fetal calf serum, 2 mM glutamine, and 
penicillin/streptomycin, 100 IU and 100 mg/ml, respectively. CHO 
clones transfected with pTEJ-8 or cotransfection with pSV2-neo were 
selected with 0.8 mg/ml Cl418 (Gibco). CA77 cells could not be suc- 
cessfully transfected by the calcium phosphate procedure; therefore 
these cells were transfected by the scrape loading method as modified 
from Fechheimer et al. [21]. DNA, 60 pg, was dissolved in 200 ~1 
PBS and added to 4 x IO6 cells, which had been seeded 3 days 
‘1, B@ 11, Xhol. Nful. Mndlll, Sa/l, EC&I, Smal, BamHl 
L-----1,/ 
Xbal. S~$ll, XMI, Nsul, Hhdlll, SaA, EcoRI, SamHI 
------l- 
Fig. 1. A schematic representation of four pTEJ vectors designed for cotransfection or transient expression studies. Only the unique restriction 
sites of the polylinker are indicated. mMt-1, mouse metallothionein I; MMTV LTR, long terminal repeat of mouse mammary tumor virus; 
Poly(A), polyadenylation signal; ApR, ampicillin resistance. 
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Fig. 2. A schematic representation f the pTEJ-8 vector. pTEJ-8 is 
identical to pTEJ-4 except for the additional eukaryotic transcription 
unit containing the SV40 early promoter, neomycin phospho- 
transferase gene (neo), and the SV40 polyadenylation signal. Only the 
unique restriction sites of the polylinker are indicated. 
previously in 100 mm diameter petri dishes (Costar). The cells were 
loaded with DNA by scraping with a rubber policeman. After 10 min 
at room temperature, the cells were seeded in fresh medium and in- 
cubated at 37°C in 10% COZ. Stably transfected cells were selected 
after 48 h by changing to medium containing 0.2 mg/ml G418, 1% 
horse serum and 0.5% fetal calf serum and transferred to 10% COZ. 
The medium for CA77 cells was a (1: 1, v/v) nutrient mixture F-10 
(Ham)/Dulbecco’s modified Eagle medium 1885 supplemented with 
lOpg/ml Insulin, 5 pg/ml transferrin, 30 nM selenous acid and 
penicillin/streptomycin, 100 IU and 100 mg/ml, respectively. 
Transfection generally gave rise to 30-50 clones per 4 x lo6 cells. 
3. RESULTS AND DISCUSSION 
3.1. Basic elements of the vectors 
Based on the pML derivative of pBR322, a series of 
eukaryotic expression vectors has been developed by in- 
corporation of different eukaryotic transcription units. 
In addition to the common sequence for prokaryotic 
propagation, all the vectors contain the SV40 
polyadenylation sequence in their transcriptional unit, 
which has been shown to be an efficient signal for the 
processing of RNA hybrids [7,22]. All vectors, except 
pTEJ-3a which is designed for expression of blunt- 
ended fragments, have a polylinker in front of the 
polyadenylation signal containing at least 3 sites of 
commonly used restriction enzymes, producing co- 
hesive protruding 5 ’ termini (Figs 1,2 and 3). We have 
chosen not to include any splice signal in the pTEJ vec- 
tors, in order to obtain small vectors which will be able 
to contain genes with a size greater than 10000 bp. Ear- 
ly studies suggested that splicing was required for the 
production and sorting of mRNA. We now know that 
many genes do not have introns and furthermore, many 
cDNAs have been efficiently expressed from vectors 
which lack splice signals (see e.g. [23,24]). 
3.2. Vectors containing constitutive promoter 
Four of the vectors (see Fig. 1) contain only a single 
eukaryotic transcription unit with a polylinker; accord- 
ingly these vectors are used in cotransfection experi- 
ments or in transient expression studies. To achieve 
constitutive and ubiquitous expression of the inserted 
cDNA, we have used the human ubiquitin promoter 
(UbC) [14], as the transcriptional control sequence, in 
3 of the vectors, pTEJ-3a, pTEJ-4 and pTEJ-8. Ubi- 
quitin is one of the most well-conserved proteins ex- 
amined so far. The amino acid sequence is unaltered 
from insect to man, and the protein is expressed in all 
cells in all eukaryotic organisms tested [25]. In trans- 
fection experiments the UbC promoter has been used to 
drive expression in a variety of cell lines (Dr B.S. 
Wulff, personal communication). This makes the ubi- 
quitin promoter an excellent ool as a constitutive pro- 
moter in a universal eukaryotic expression vector. 
As shown in Table I, tPA and pro-glucagon have 
been synthesized by CHO cells transfected with 
pTEJ-3a containing the respective cDNA. pTEJ-4 de- 
rivatives containing cDNAs encoding PSTI, pro-NPY, 
and cystatin C have been expressed in CHO cells. 
Similarly, the ubiquitin promoter was used to drive the 
expression of pro-NPY and cystatin C in CA77 cells, a 
well-differentiated, neuroendocrine cell line [19]. The 
median expression of protein from the ubiquitin pro- 
moter in populations of stably transfected clones was 
between 1 and several hundred pmol per lo6 cells per 
24 h. The difference in the expression level is con- 
ceivably due to differences in the cellular handling of 
the different mRNAs in question, and/or the stability 
of the protein in the tissue culture medium. The max- 
imal biosynthesis observed in transfected CHO cells 
was 620 pmol cystatin C per lo6 cells per 24 h (Table I). 
This high secretion level, which corresponds to 10 mg 
cystatin C/liter of culture medium, can possibly be ex- 
plained by the fact that the cystatin C cDNA contains 
both the optimal Kozak initiation consensus AC- 
CATGG and its qwn polyadenylation signal, 
AATAAA [26]. It sho&l also be noted that protease 
inhibitors are more stable than hornlone precursors, 
which are in fact enzyme substrates. The ubiquitin pro- 
moter gave a higher yield of the exogenous protein in 
CHO cells as compared to CA77 cells. This could be 
due to the different transfection procedures or to basic 
differences between the two mammalian cell lines. It 
should be noted that, in the CA77 cells, the expression 
levels of protein correspond to the amount of en- 
dogenously produced peptide hormone, calcitonin gene 
related peptide (CGRP), 20-25 pmol/106 cells/24 h. 
3.3. Vectors containing inducible promoters 
The mouse metallothionein I promoter and the pro- 
moter in the long terminal repeat from the mouse mam- 
mary tumor virus were used as inducible promoters. 
The mouse metallothionein I promoter and 5 ’ flanking 
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Polylinker for pTEJ-Sand 7 : 
BglII Sac1 Hind111 
ATCTA=CGmGCGAA=GGCTGCAGG=GGATCTGAATTCGmGCCCCGGmT, I-- 
XhoI NruI PSI1 EcoRl SnMlI 
Polylinker for pTEJ-4and 8 : 
H,udIlI SO11 Sac1 BumHI 
AAGCTTGGCTGCAGG=GGATCTGAATTCG=GCCCCGGzT 
PHI EcoRI .snmI 
Fig. 3. The nucleotide sequence of the polylinkers from the pTEJ vectors. The cleavage site for restriction enzymes, which recognize 6 bases, 
are indicated. The unique restriction sites in the polylinker of the different vectors are shown in Figs 1 and 2. 
sequences have previously been used to confer metal 
responsiveness to genes or cDNAs transfected into 
mammalian cells [ 151. The metal responsiveness of this 
promoter used in pTEJ-5 in a 12 bp DNA motif which 
is repeated 5 times [ 151. CHO and CA77 cells were 
transfected with pTEJ-5 including cDNA encoding 
PAI-I and pro-NPY. In the basal uninduced state the 
median expression levels were below 0.5 pmol/106 
Table I 
Biosynthesis and secretion of specific protein by stable clones of CHO and CA77 cells transfected with plasmids derived 























pTEJ-3A UbC tPA CHO 0.9 1.2 
pTEJ-3A UbC pro-glucagon CHO 2.3 7.8 
pTEJ-4 UbC PSTI CHO 18.4 48.7 
pTEJ-4 UbC PSTI CA77 3.4 20.4 
pTEJ-4 UbC pro-NP Y CHO 27.3 106.3 
pTEJ-4 UbC pro-NPY CA774 6.5 20.4 
pTEJ-4 UbC cystatin C CHO 240.5 490.0 
pTEJ-5 mMt-I pro-NPY CHO 1.1 5.6 
pTEJ-5 mMt-I PAI-1 CA77 1.8 16.5 
pTEJ-5 mMt-I PAI-1 CHO 2.4 13.4 
pTEJ-7 MMTV cystatin C CHO 1.6 5.4 
pTEJ-7 MMTV cystatin C CA77 0.2 1.0 
_ _ 6 
_ - 8 
_ - 6 
_ _ 15 
- - 16 
_ _ 8 
- - 12 
310 1220 16 
350 850 13 
470 1230 10 
510 800 14 
130 180 8 
a pTUB 191, human tPa was excised from a pBR322 clone (obtained from Dr S. Degen, Department of Pediatrics, 
University of Cincinnati, OH) as a 2182 bp fragment obtained by partial Sac1 and BgllI double digestion, where the 
Bg/lI in position 311 and Sac1 in position 1541 were left undigested. This fragment was ligated into pICl9R, re-excised 
as a blunt-ended EcoRV and Hind111 fragment and ligated into the HpaI site of pTEJ-3A. pTUB 239, hamster pro- 
glucagon was excised from psh-Glu [31] (obtained from Dr G.I. Bell, University of Chicago) as a 992 bp D&I 
fragment and inserted into the HpaI site of pTEJ-3A. pTUB 196, human PSTI was excised from pTICl1 [32] 
(obtained from Drs N. Tomita, A. Hori and K. Matsubara, Osaka University, Japan) as an EcoRI fragment and 
ligated into the polylinker of pTEJ-4. pTUB 214, human NPY [33] (originally obtained from Drs C.D. Minth and 
J.E. Dixon, Perdue University, IN) was excised as a 387 bp BamHI fragment from ~753 [13] and inserted into pTEJ-4. 
pTUB 236, human cystatin C was excised from p6C [26] (obtained from Dr M. Abrahamson, University of Lund) 
as an EcoRI fragment and cloned into the EcoRI site of pTEJ-4. pTUB 213, was constructed as pTUB 214, but with 
pTEJ-5 as the recipient vector. pTUB 223, human PAI-I was excised from pPAI-l-Al [34] (obtained from Drs P.A. 
Andreasen and K. Dano, Finsen Laboratory, Rigshospitalet, Copenhagen), as a 1314 bp EcoRI to Bgfll fragment and 
ligated into pTEJ-5. pTUB 237 was constructed as pTUB 236, but with pTEJ-7 as the recipient vector 
b The values of the specific proteins secreted in the cell culture medium are given in pmol/106 cells/24 h. The specific 
proteins were measured in medium collected after 24 h. Glucagon [35], NPY [36], PST1 [37], and cystatin C (Vogel 
et al., in preparation) were analyzed by radioimmunoassays. PAI- and tPA were determined by ELISA [38] 
’ The levels of secreted proteins seen with the mMt-I and MMTV promoters correspond to maximal induction obtained 
with 5 x lOWe’ M cadmium chloride and with 2 x 10e6 M dexamethasone r spectively 
d Transient expression, 72 h after transfection 
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cells/24 h. The NPY and PAI-I synthesizing clones 
selected for the highest secretion level, synthesized be- 
tween 5.6 and 16.5 fimol/106 cells/24 h, in the induced 
state (Table I). As shown in Fig. 4 and Table I, the 
secretion of NPY from the pTEJ-5 vectors could be in- 
creased by 12.3-fold, compared to the uninduced level, 
by treatment of the cells with cadmium. Among the dif- 
ferent populations of clones, the median induction was 
3.1-4.7-fold. Maximal induction was achieved with 
0.5 x 10e5 M CdCL with a rather narrow working 
range of stimulatory concentrations, due to the toxic 
effect of the cadmium ions at high concentrations 
(Fig. 4). The mouse metallothionein promoter can also 
be induced with other divalent cations [27]; however, 
this was not tested in the present study. The long ter- 
minal repeat of the mouse mammary tumor virus DNA 
has proven to be useful for inducible expression of 
cloned genes or cDNAs in mammalian cells [ 161. This 
promoter contains the viral transcription promoter 
signals as well as the DNA sequences that confer 
glucocorticoid induction of expression. The mouse 
mammary tumor virus promoter of pTEJ-7 was induc- 
ed by dexamethasone, and showed similar 
characteristics as the mouse metallothionein I pro- 
moter, both in respect of basal protein production and 
degree of induction (Fig. 4, Table I). However, in this 
case, a very broad range of concentrations of the in- 
ducer, dexamethasone, could be used. Almost maximal 
induction was achieved with concentrations of dex- 
amethasone from 10e9 to 10m5 M (Fig. 4). Interesting- 
ly, the mouse mammary tumor virus promoter 
appeared to function poorly in the CA77 cells. In the 
basal state, the amount of cystatin C synthesized was 
only around one-tenth of that synthesized with the 
other vectors in these cells (Table I). Furthermore, even 
in the most inducible clones, the secretion of protein 
only increased by a factor of 1.8. It should be noted 
that the subclone of CA77 cells used in the present 
study synthesized large amounts of CGRP rather than 
calcitonin as in the case of most CA77 cells. The dif- 
ferential RNA splicing which leads to the generation of 
either calcitonin or CGRP from the same transcript is 
in fact regulated by corticosteroids [28]. It is therefore 
possible that for example the glucocorticoid receptor in 
this particular CA77 subclone does not function ap- 
propriately, neither in the regulation of the RNA splic- 
ing nor in the stimulation of the mouse mammary 
tumor virus promoter in the transfection vector. 
3.4. Vector containing selective marker 
The eukaryotic expression vector, pTEJ-8, is iden- 
tical to pTEJ-4, except for an additional transcription 
unit containing the selective marker, neomycin phos- 
photransferase gene (Figs 1, 2). About 300 G418- 
resistant clones per lo6 cells/pg pTEJ-8 were obtained 
following transfection with pTEJ-8 or pTEJ-8 deriva- 






log CdC12 cont., M 
Fig. 4. Cadmium induction of a stable CHO clone (CHO D-10) 
transfected with pTEJ-5 containing human PAL1 cDNA. PAL1 was 
measured in 24 h medium collected after treatment with increasing 
concentrations of cadmium chloride. 
is driven by the SV40 early promoter. In addition to the 
promoter, the 326 bp HindIII-PvuII SV40 fragment 
also contains the origin of DNA replication [ 12,22,29]. 
This should allow this vector to replicate to a level 
greater than lo5 copies per cell when transfected into 
e.g. COS cells [30]. The COS cell line produces high 
levels of large T antigen and is therefdre permissive for 
SV40 DNA replication [30]. This high copy number of 
plasmids should ensure high level expression of the pro- 
tein in transient experiments. 
3.5. Conclusion 
The pTEJ vectors are shown to be efficient for the 
expression of cloned nucleotide sequences in eukaryotic 
cells. Although they have elements in common with 
other previously described eukaryotic expression vec- 
tors, the pTEJ vectors have several advantages which 
make them particularly useful. (i) The human ubiquitin 
(UbC) promoter is a very powerful constitutive pro- 
moter, which gives ubiquitous expression. (ii) The two 
different inducible promoters of the series can be in- 
log dexamethasone cont., M 
Fig. 5. Dexamethasone induction of a stable CHO clone (CHO G-10) 
transfected with pTEJ-5 containing human cystatin C cDNA. 
Cystatin C was measured in medium collected after 24 h, following 
treatment with increasing concentrations of dexamethasone. 
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duced up to 12-fold. (iii) The polylinker of the pTEJ 
vectors, except pTEJ-3a which has a single HpaI blunt 
end site, contain at least 3 sites for the most commonly 
used restriction enzymes, HindIII, EcoRI and BamHI. 
(iv) The neomycin phosphotransferase gene is included 
in the series as an eukaryotic selection marker. (v) The 
vectors, especially pTEJ-5, are small. We believe that 
the pTEJ series of vectors will have numerous applica- 
tions, for example in structure-function studies of 
eukaryotic proteins. 
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